 |
 |

Risk of Hemolytic Uremic Syndrome From Antibiotic Treatment of Escherichia coli O157:H7 Colitis
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: In their meta-analysis, Dr Safdar and colleagues1 concluded that antibiotic exposure during Escherichia coli O157:H7 colitis was not associated with an increased risk of hemolytic uremic syndrome (HUS). Because the included studies were very heterogeneous, however, conclusions based on a single risk estimate may be misleading.
In Figure 1 of the article, 2 of 9 studies reported significantly increased odds ratios (ORs); 6 studies showed no association; and 1 study, which treated patients with fosfomycin, showed a decreased risk of HUS. Safdar et al treated the 2 studies with increased ORs as statistical outliers and averaged these effects against the much larger studies.
Part of this heterogeneity may be related to underlying biological mechanisms. Different strains of E coli O157:H7 respond differently in their production of Shiga-toxin with exposure to subinhibitory concentrations of antibiotics; some strains increase Shiga-toxin production while others do not.2 This is believed to . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
, , , , , , , and
JAMA. ;280():605-613.
FULL TEXT
Risk of Hemolytic Uremic Syndrome After Antibiotic Treatment of Escherichia coli O157:H7 Enteritis: A Meta-analysis
, , , and
JAMA. ;288():996-1001.
FULL TEXT
|